Prazosin initiation and dose titration in a patient with posttraumatic stress disorder on concurrent carvedilol.
PTSD therapy
dual alpha antagonist
nightmare
prazosin
Journal
The mental health clinician
ISSN: 2168-9709
Titre abrégé: Ment Health Clin
Pays: United States
ID NLM: 101728585
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
20
9
2019
Statut:
epublish
Résumé
One mechanism involved in the pathophysiology of posttraumatic stress disorder (PTSD) is increased noradrenergic stimulation. Prazosin, a commonly utilized treatment for PTSD nightmares, works to block noradrenergic stimulation of the alpha-1 adrenoreceptor. Dual antagonism of this receptor would be expected to increase risk of adverse effects. Carvedilol has both alpha-1 adrenergic and nonselective beta-adrenoreceptor antagonist activity. To our knowledge, there is no clinical guidance on use of prazosin in patients concomitantly prescribed carvedilol for hypertension. This case describes the successful titration of prazosin for PTSD symptoms in a 49-year-old male concurrently prescribed carvedilol for hypertension. This patient had a previous unsuccessful prazosin trial due to adverse effects. His second trial of prazosin was efficacious and well tolerated using individualized titration with close monitoring by mental health clinical pharmacy specialists in the pharmacist-managed prazosin titration clinic. This case details the importance of utilizing caution and close follow-up in prazosin dose titration in patients prescribed concomitant alpha-1 antagonists. This appears to be the first case report describing the successful dose titration of prazosin for PTSD in a patient on a concurrent alpha-1 antagonist antihypertensive agent.
Identifiants
pubmed: 31534876
doi: 10.9740/mhc.2019.09.326
pii: MHC-D-18-00051
pmc: PMC6728122
doi:
Types de publication
Case Reports
Langues
eng
Pagination
326-330Déclaration de conflit d'intérêts
Disclosures: The authors report no actual or potential conflicts of interest associated with this article.
Références
Life Sci. 2000 Nov 24;68(1):29-39
pubmed: 11132243
Am J Psychiatry. 2003 Feb;160(2):371-3
pubmed: 12562588
J Geriatr Psychiatry Neurol. 2003 Sep;16(3):165-71
pubmed: 12967060
J Cardiovasc Pharmacol. 1992;19 Suppl 1:S18-22
pubmed: 1378144
Biol Psychiatry. 2007 Apr 15;61(8):928-34
pubmed: 17069768
Am J Health Syst Pharm. 2008 Apr 15;65(8):716-22
pubmed: 18387899
J Psychosom Res. 2012 Feb;72(2):89-96
pubmed: 22281448
Am J Psychiatry. 2013 Sep;170(9):1003-10
pubmed: 23846759
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
N Engl J Med. 2018 Feb 8;378(6):507-517
pubmed: 29414272
Psychopharmacology (Berl). 1994 May;114(4):559-65
pubmed: 7855217
Arch Gen Psychiatry. 1993 Apr;50(4):266-74
pubmed: 8466387